| Year |
Citation |
Score |
| 2024 |
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, ... ... Tabouret E, et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2400049. PMID 39356975 DOI: 10.1200/JCO.24.00049 |
0.458 |
|
| 2024 |
Snacel-Fazy E, Soubéran A, Grange M, Joseph K, Colin C, Morando P, Luche H, Pagano A, Brustlein S, Debarbieux F, Toutain S, Siret C, van de Pavert SA, Rougon G, Figarella-Branger D, ... ... Tabouret E, et al. SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment. Cell Death & Disease. 15: 676. PMID 39278921 DOI: 10.1038/s41419-024-07056-z |
0.772 |
|
| 2024 |
Soubéran A, Jiguet-Jiglaire C, Toutain S, Morando P, Baeza-Kallee N, Appay R, Boucard C, Graillon T, Meyer M, Farah K, Figarella-Branger D, Tabouret E, Tchoghandjian A. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models. Neuro-Oncology. PMID 39252580 DOI: 10.1093/neuonc/noae184 |
0.718 |
|
| 2024 |
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances. 6: vdae038. PMID 38590763 DOI: 10.1093/noajnl/vdae038 |
0.8 |
|
| 2024 |
Graillon T, Salgues B, Horowitz T, Padovani L, Appay R, Tabouret E, Guedj E, Chinot O. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. Journal of Neuro-Oncology. PMID 38451361 DOI: 10.1007/s11060-024-04622-5 |
0.522 |
|
| 2023 |
Harlay V, Appay R, Bequet C, Petrirena G, Campello C, Barrié M, Autran D, Graillon T, Boissonneau S, Dufour H, Figarella-Branger D, Padovani L, Barlier A, Nanni I, Tabouret E, et al. Radio-chemotherapy feasibility for biopsy-only unresectable wild-type glioblastomas (BO-GBM). Neuro-Oncology Practice. 10: 536-543. PMID 38009116 DOI: 10.1093/nop/npad028 |
0.634 |
|
| 2023 |
Ariey-Bonnet J, Berges R, Montero MP, Mouysset B, Piris P, Muller K, Pinna G, Failes TW, Arndt GM, Morando P, Baeza-Kallee N, Colin C, Chinot O, Braguer D, Morelli X, ... ... Tabouret E, et al. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. Ebiomedicine. 95: 104752. PMID 37572644 DOI: 10.1016/j.ebiom.2023.104752 |
0.613 |
|
| 2023 |
Baeza-Kallee N, Bergès R, Hein V, Cabaret S, Garcia J, Gros A, Tabouret E, Tchoghandjian A, Colin C, Figarella-Branger D. Deciphering the Action of Neuraminidase in Glioblastoma Models. International Journal of Molecular Sciences. 24. PMID 37511403 DOI: 10.3390/ijms241411645 |
0.782 |
|
| 2023 |
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Tabouret E, et al. Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023). Trends in Cancer. PMID 36997420 DOI: 10.1016/j.trecan.2023.02.006 |
0.718 |
|
| 2022 |
Montégut C, Guillamo JS, Ducray F, Dehais C, Cohen-Jonathan Moyal E, Desenclos C, Petit A, Seizeur R, Bekaert L, Gaultier C, Motuo Fotso MJ, Blonski M, Frenel JS, Vauléon E, Langlois O, ... ... Tabouret E, et al. Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade -Mutant Gliomas: A French POLA Network Study. Cancers. 14. PMID 36428602 DOI: 10.3390/cancers14225509 |
0.401 |
|
| 2022 |
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Tabouret E, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends in Cancer. PMID 36400694 DOI: 10.1016/j.trecan.2022.09.005 |
0.736 |
|
| 2022 |
Lombardi G, Poliani PL, Manara R, Berhouma M, Minniti G, Tabouret E, Razis E, Cerretti G, Zagonel V, Weller M, Idbaih A. Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview. Cancers. 14. PMID 35954310 DOI: 10.3390/cancers14153646 |
0.319 |
|
| 2022 |
Chanez B, Appay R, Guille A, Lagarde A, Colin C, Adelaide J, Denicolai E, Jiguet-Jiglaire C, Bequet C, Graillon T, Boissonneau S, Nanni-Metellus I, Dufour H, Figarella-Branger D, Chinot O, ... Tabouret E, et al. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy. Journal of the Neurological Sciences. 436: 120207. PMID 35259554 DOI: 10.1016/j.jns.2022.120207 |
0.764 |
|
| 2022 |
Grimaldi S, Harlay V, Appay R, Bequet C, Petrirena G, Campello C, Barrié M, Autran D, Boissonneau S, Graillon T, Figarella-Branger D, Nanni I, Chinot O, Tabouret E. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients. Journal of Neuro-Oncology. 156: 615-623. PMID 34994963 DOI: 10.1007/s11060-022-03943-7 |
0.411 |
|
| 2022 |
Jiguet-Jiglaire C, Boissonneau S, Denicolai E, Hein V, Lasseur R, Garcia J, Romain S, Appay R, Graillon T, Mason W, Carpentier AF, Brandes AA, Ouafik L', Wick W, Baaziz A, ... ... Tabouret E, et al. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study. Acta Neuropathologica Communications. 10: 1. PMID 34980260 DOI: 10.1186/s40478-021-01305-4 |
0.78 |
|
| 2021 |
Picart T, Barritault M, Poncet D, Berner LP, Izquierdo C, Tabouret E, Figarella-Branger D, Idbaïh A, Bielle F, Bourg V, Vandenbos FB, Moyal EC, Uro-Coste E, Guyotat J, Honnorat J, et al. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neuro-Oncology Advances. 3: vdab061. PMID 34056608 DOI: 10.1093/noajnl/vdab061 |
0.4 |
|
| 2021 |
Tabouret E, Fabbro M, Autran D, Hoang-Xuan K, Taillandier L, Ducray F, Barrie M, Sanson M, Kerr C, Cartalat-Carel S, Loundou A, Guillevin R, Mokhtari K, Figarella-Branger D, Delattre JY, et al. TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study. The Oncologist. PMID 33783067 DOI: 10.1002/onco.13765 |
0.455 |
|
| 2021 |
Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyrière H, Mougel G, Autran D, Tabouret E, Figarella-Branger D, Barlier A, Kalamarides M, Dufour H, Colin T, Chinot O. Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro-Oncology. PMID 33556177 DOI: 10.1093/neuonc/noab019 |
0.36 |
|
| 2020 |
Argüello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, Camosseto V, Samad B, Tsui J, Yan P, Boissonneau S, Figarella-Branger D, Gatti E, Tabouret E, Krummel MF, et al. SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution. Cell Metabolism. 32: 1063-1075.e7. PMID 33264598 DOI: 10.1016/j.cmet.2020.11.007 |
0.371 |
|
| 2020 |
Lombardi G, Barresi V, Castellano A, Tabouret E, Pasqualetti F, Salvalaggio A, Cerretti G, Caccese M, Padovan M, Zagonel V, Ius T. Clinical Management of Diffuse Low-Grade Gliomas. Cancers. 12. PMID 33081358 DOI: 10.3390/cancers12103008 |
0.313 |
|
| 2020 |
Graillon T, Roche C, Basset N, Mougel G, Meyer M, Farah K, Boissonneau S, Fuentes S, Tabouret E, Campello C, Appay R, Figarella-Branger D, Chinot O, Dufour H, Romanet P, et al. Brief CommunicationCirculating tumor DNA is present in the most aggressive meningiomas. Neuro-Oncology Advances. 2: vdaa068. PMID 32642718 DOI: 10.1093/noajnl/vdaa068 |
0.423 |
|
| 2020 |
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, et al. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31969329 DOI: 10.1158/1078-0432.Ccr-19-2109 |
0.489 |
|
| 2019 |
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. PMID 31832685 DOI: 10.1093/Neuonc/Noz124 |
0.712 |
|
| 2019 |
Dardaud LM, Bris C, Desquiret-Dumas V, Boisselier B, Tabouret E, Mokhtari K, Figarella-Branger D, Rousseau A, Procaccio V. High mitochondrial DNA copy number is associated with longer survival in young patients with glioblastoma. Neuro-Oncology. PMID 31095694 DOI: 10.1093/Neuonc/Noz072 |
0.505 |
|
| 2019 |
Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016. Journal of Neuro-Oncology. PMID 30859482 DOI: 10.1007/S11060-019-03141-Y |
0.651 |
|
| 2019 |
Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E. Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients. Anticancer Research. 39: 1035-1041. PMID 30711992 DOI: 10.21873/Anticanres.13210 |
0.648 |
|
| 2019 |
Chanez B, Appay R, Guille A, Lagarde A, Adelaide J, Denicolai E, Campello C, Tchoghandjian A, Petrirena G, Colin C, Barrie M, Baeza-Kallee N, Boucard C, Jiguet-Jiglaire C, Graillon T, ... ... Tabouret E, et al. Genomic analysis of paired IDHwt glioblastoma (GB) to reveal recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT). Journal of Clinical Oncology. 37: e13535-e13535. DOI: 10.1200/Jco.2019.37.15_Suppl.E13535 |
0.817 |
|
| 2019 |
Garcilazo YJ, Soussain C, Tabouret E, Ahle G, Schimitt A, Waultier A, Blonski M, Liou-Schischmanoff A, Hoang-Xuan K, Houillier C. P14.118 Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study Neuro-Oncology. 21: iii96-iii96. DOI: 10.1093/Neuonc/Noz126.353 |
0.33 |
|
| 2019 |
Garnier L, Dehais C, Curtit E, Tabouret E, Ramirez C, Vauleon E, Bourg V, Boone M, Figarella-Branger D, Ducray F. P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study Neuro-Oncology. 21: iii85-iii85. DOI: 10.1093/Neuonc/Noz126.311 |
0.541 |
|
| 2019 |
Chanez B, Appay R, Guille A, Lagarde A, Bequet C, Jiguet-Jiglaire C, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E. P13.09 Genomic analysis of paired IDHwt glioblastoma (GB) reveals recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT) Neuro-Oncology. 21: iii64-iii64. DOI: 10.1093/Neuonc/Noz126.230 |
0.568 |
|
| 2019 |
Picart T, Barritault M, Tabouret E, Idbaih A, Izquierdo Gracia C, Poncet D, Honnorat J, Meyronet D, Guyotat J, Ducray F. OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults Neuro-Oncology. 21: iii12-iii12. DOI: 10.1093/Neuonc/Noz126.038 |
0.347 |
|
| 2019 |
Tabouret E, Tsvetkov P, Eyraud R, Peel T, Malesinski S, Figarella-Branger D, Chinot O, Devred F. OS1.7 Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls Neuro-Oncology. 21: iii7-iii7. DOI: 10.1093/Neuonc/Noz126.020 |
0.444 |
|
| 2019 |
Montégut C, Guillamo J, Ducray F, Dehais C, Chinot O, Cohen-Jonathan Moyal E, Le Rhun E, Loiseau H, Appay R, Figarella-Branger D, Delattre J, Tabouret E. Characteristics and patterns of care of high-grade IDH-mutant gliomas in elderly patients: A French POLA network study Annals of Oncology. 30: v147. DOI: 10.1093/Annonc/Mdz243.010 |
0.533 |
|
| 2018 |
Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study. Annals of Hematology. PMID 30535802 DOI: 10.1007/S00277-018-3564-6 |
0.365 |
|
| 2018 |
Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathologica Communications. 6: 89. PMID 30193580 DOI: 10.1186/S40478-018-0594-1 |
0.746 |
|
| 2018 |
Appay R, Tabouret E, Macagno N, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D. IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. Neuro-Oncology. PMID 29522183 DOI: 10.1093/Neuonc/Noy014 |
0.708 |
|
| 2018 |
Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L. Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression. Oncotarget. 9: 10175-10183. PMID 29515801 DOI: 10.18632/Oncotarget.23699 |
0.585 |
|
| 2018 |
Tsvetkov PO, Tabouret E, Roman AY, Romain S, Bequet C, Ishimbaeva O, Honoré S, Figarella-Branger D, Chinot O, Devred F. Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool. Oncotarget. 9: 9391-9399. PMID 29507697 DOI: 10.18632/Oncotarget.24317 |
0.528 |
|
| 2018 |
Tabouret E, Compes P, Etcheverry A, Colin C, Appay R, Cordier N, Chinot OL, Delinguette H, Girard N, Dufour H, Metellus P, Figarella-Branger D. Molecular and neuro-radiological characteristics of diffuse grade II and III gliomas involving the insula. Journal of Clinical Oncology. 36: e14050-e14050. DOI: 10.1200/Jco.2018.36.15_Suppl.E14050 |
0.688 |
|
| 2017 |
Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, Boucard C, Graillon T, Girard N, Chinot O. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. Journal of Neuro-Oncology. PMID 28265824 DOI: 10.1007/S11060-017-2385-0 |
0.364 |
|
| 2017 |
Graillon T, Sanson M, Peyre M, Peyrière H, Autran D, Kalamarides M, Roche P, Fuentes S, Tabouret E, Barrie M, Campello C, Idbaih A, Dufour H, Chinot OL. A phase II of everolimus and octreotide for patients with refractory and documented progressive meningioma (CEVOREM). Journal of Clinical Oncology. 35: 2011-2011. DOI: 10.1200/Jco.2017.35.15_Suppl.2011 |
0.384 |
|
| 2017 |
Graillon T, Sanson M, Peyre M, Peyrière H, Autran D, Kalamarides M, Roche P, Fuentes S, Tabouret E, Barrie M, Campello C, Idbaih A, Boucekine M, Figarella-Branger D, Barlier A, et al. MNGI-13. FINAL ANALYSIS OF PHASE II COMBINING EVEROLIMUS AND OCTREOTIDE FOR PATIENTS WITH REFRACTORY AND DOCUMENTED PROGRESSIVE MENINGIOMA (CEVOREM) Neuro-Oncology. 19: vi134-vi135. DOI: 10.1093/Neuonc/Nox168.551 |
0.464 |
|
| 2016 |
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, et al. Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial. Neuro-Oncology. PMID 27994065 DOI: 10.1093/Neuonc/Now238 |
0.308 |
|
| 2016 |
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, et al. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathologica. PMID 27573687 DOI: 10.1007/S00401-016-1611-8 |
0.722 |
|
| 2016 |
Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, Padovani L, Figarella-Branger D, Chinot O. Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma. Journal of Neuro-Oncology. 130: 431-437. PMID 27566180 DOI: 10.1007/S11060-016-2251-5 |
0.803 |
|
| 2016 |
Figarella-Branger D, Lechapt-Zalcman E, Tabouret E, Jünger S, de Paula AM, Bouvier C, Colin C, Jouvet A, Forest F, Andreiuolo F, Quintin-Roue I, Machet MC, Heitzmann A, Milin S, Sevestre H, et al. Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. Neuro-Oncology. PMID 26984744 DOI: 10.1093/Neuonc/Now025 |
0.747 |
|
| 2016 |
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, et al. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget. PMID 26921265 DOI: 10.18632/Oncotarget.7612 |
0.32 |
|
| 2016 |
Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D. Molecular heterogeneity of glioblastomas: does location matter? Oncotarget. 7: 902-13. PMID 26637806 DOI: 10.18632/Oncotarget.6433 |
0.776 |
|
| 2016 |
Chinot OL, Garcia J, Romain S, Revil C, Cloughesy T, Mason WP, Nishikawa R, Henriksson R, Saran F, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Kerloeguen Y, ... ... Tabouret E, et al. Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. Journal of Clinical Oncology. 34: 2020-2020. DOI: 10.1200/Jco.2016.34.15_Suppl.2020 |
0.334 |
|
| 2016 |
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Lebouil L, Ducray F, Idbaih A, Moktari K, Jouvet A, uro-Coste E, Delattre J, Figarella-Branger D. Validation of the new glioma WHO classification in the french POLA network: Analysis of 1041 cases. Journal of Clinical Oncology. 34: 2015-2015. DOI: 10.1200/Jco.2016.34.15_Suppl.2015 |
0.525 |
|
| 2016 |
Denicolai E, Figarella-Branger D, Chinot O, Tabouret E. ANGI-06. MMP9 AND MMP2 EXHIBIT DISTINCT INTRATUMORAL EXPRESSION PATTERN IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA (GB) Neuro-Oncology. 18: vi16-vi16. DOI: 10.1093/Neuonc/Now212.061 |
0.485 |
|
| 2016 |
Tsvetkov PO, Tabouret E, Roman A, Ishimbaeva O, Kubatiev AA, Romain S, Figarella-Branger D, Chinot O, Devred F. ACTR-34. ANALYSIS OF PLASMATIC SIGNATURE OF GLIOBLASTOMA PATIENTS OBTAINED BY DIFFERENTIAL SCANNING CALORIMETRY REVEALS THREE PROGNOSTIC CLUSTERS Neuro-Oncology. 18: vi9-vi9. DOI: 10.1093/Neuonc/Now212.032 |
0.455 |
|
| 2016 |
Chinot O, Garcia J, Romain S, Revil C, Cloughesy T, Mason W, Nishikawa R, Henriksson R, Saran F, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea DM, Brandes AA, Kerloeguen Y, ... ... Tabouret E, et al. ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio Neuro-Oncology. 18: vi5-vi5. DOI: 10.1093/Neuonc/Now212.018 |
0.313 |
|
| 2015 |
Tabouret E, Bequet C, Denicolaï E, Barrié M, Nanni I, Metellus P, Dufour H, Chinot O, Figarella-Branger D. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 41: 1685-90. PMID 26454767 DOI: 10.1016/J.Ejso.2015.09.012 |
0.44 |
|
| 2015 |
Tabouret E, Labussière M, Alentorn A, Schmitt Y, Marie Y, Sanson M. LRP1B deletion is associated with poor outcome for glioblastoma patients. Journal of the Neurological Sciences. 358: 440-3. PMID 26428308 DOI: 10.1016/j.jns.2015.09.345 |
0.33 |
|
| 2015 |
Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, et al. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium. Acta Neuropathologica. 130: 439-40. PMID 26195323 DOI: 10.1007/S00401-015-1461-9 |
0.459 |
|
| 2015 |
Tabouret E, Boudouresque F, Farina P, Barrié M, Bequet C, Sanson M, Chinot O. MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma. Neuro-Oncology. 17: 1174-6. PMID 26142442 DOI: 10.1093/Neuonc/Nov094 |
0.382 |
|
| 2015 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T, Boucard C, Nanni I, Padovani L, Ouafik L, Figarella-Branger D, Chinot O. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget. 6: 11664-75. PMID 25860928 DOI: 10.18632/Oncotarget.3256 |
0.795 |
|
| 2015 |
Tabouret E, Goncalves A, Bertucci F, Pierga J, Petit T, Levy C, Ferrero J, Campone M, Gligorov J, Lerebours F, Roche HH, Bachelot TD, Toiron Y, Borg J, Chinot OL, et al. Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study. Journal of Clinical Oncology. 33: 600-600. DOI: 10.1200/Jco.2015.33.15_Suppl.600 |
0.351 |
|
| 2015 |
Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquieres H, Houot R, Delwail V, Soubeyran P, Gressin R, Gyan E, Chinot OL, Taillandier L, Tanguy M, Omuro AMP, et al. Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial. Journal of Clinical Oncology. 33: 2035-2035. DOI: 10.1200/Jco.2015.33.15_Suppl.2035 |
0.35 |
|
| 2015 |
Denicolai E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Baeza-Kallee N, Fina F, Chinot OL, Figarella-Branger D. Differential molecular expression profile according to glioblastoma (GB) location. Journal of Clinical Oncology. 33: 2030-2030. DOI: 10.1200/Jco.2015.33.15_Suppl.2030 |
0.773 |
|
| 2015 |
Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, et al. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium Acta Neuropathologica. 130: 439-440. DOI: 10.1007/s00401-015-1461-9 |
0.359 |
|
| 2014 |
Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S, Braguer D. End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo. Oncotarget. 5: 12769-87. PMID 25473893 DOI: 10.18632/Oncotarget.2646 |
0.551 |
|
| 2014 |
Tabouret E, Chinot O, Sanson M, Loundou A, Hoang-Xuan K, Delattre JY, Idbaih A. Predictive biomarkers investigated in glioblastoma. Expert Review of Molecular Diagnostics. 14: 883-93. PMID 25096963 DOI: 10.1586/14737159.2014.945436 |
0.361 |
|
| 2014 |
Lombardi G, Di Stefano AL, Farina P, Zagonel V, Tabouret E. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treatment Reviews. 40: 951-9. PMID 24909312 DOI: 10.1016/J.Ctrv.2014.05.007 |
0.34 |
|
| 2014 |
Tabouret E, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Carpentier A, Sanson M, Metellus P, Figarella-Branger D, Ouafik L, Chinot O. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro-Oncology. 16: 392-9. PMID 24327581 DOI: 10.1093/Neuonc/Not226 |
0.534 |
|
| 2014 |
Autran D, Tabouret E, Barrie M, Matta M, Monserrat C, Boucard C, Terciolo A, Loundou A, Metellus P, Dufour H, Figarella-Branger D, Chinot OL. Leptomeningeal gliomatosis: A single institution retrospective study of 31 patients. Journal of Clinical Oncology. 32: e13017-e13017. DOI: 10.1200/Jco.2014.32.15_Suppl.E13017 |
0.48 |
|
| 2014 |
De Cock L, Sala Q, Barrie M, Boucard C, Terciolo A, Graillon T, Metellus P, Autran D, Tabouret E, Padovani L, Figarella-Branger D, Dufour H, Chinot OL. Patterns of care and outcome for patients with recurrent glioblastoma (GB). Journal of Clinical Oncology. 32: e13007-e13007. DOI: 10.1200/Jco.2014.32.15_Suppl.E13007 |
0.667 |
|
| 2014 |
Barlog C, Tabouret E, Sanson M, Idbaih A, Houillier C, Laigle-Donadey F, Alentorn A. “Salvage” neoadjuvant bevacizumab in newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. 32: 2083-2083. DOI: 10.1200/Jco.2014.32.15_Suppl.2083 |
0.367 |
|
| 2014 |
Tabouret E, Boudouresque F, Denicolai E, Barrie M, Boucard C, Metellus P, Autran D, Terciolo A, Figarella-Branger D, Ouafik L, Chinot OL. Plasma levels and tumor tissue RNA of MMP2 and MMP9 exhibit similar distribution in newly diagnosed and recurrent glioblastoma (GB). Journal of Clinical Oncology. 32: 2074-2074. DOI: 10.1200/Jco.2014.32.15_Suppl.2074 |
0.498 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot OL. Expression profile of angiogenic factors in paired initial and recurrent glioblastoma. Journal of Clinical Oncology. 32: 2060-2060. DOI: 10.1200/Jco.2014.32.15_Suppl.2060 |
0.789 |
|
| 2014 |
Tabouret E, Boucard C, Barrie M, Autran D, Bruder N, Chinot O. SM-08 * NEURO-ONCOLOGICAL PATIENTS ADMITTED IN INTENSIVE-CARE UNIT (ICU): PATIENT'S CHARACTERISTICS, PREDICTIVE FACTORS OF DEATH IN ICU AND FUNCTIONAL OUTCOME Neuro-Oncology. 16: v207-v207. DOI: 10.1093/Neuonc/Nou277.7 |
0.373 |
|
| 2014 |
Tabouret E, Reyes-Botero G, Dehais C, Daros M, Barrie M, Matta M, Petrirena G, Autran D, Duran A, Boucard C, Delattre JY, Chinot O. CN-18 * RELATIONSHIPS BETWEEN DOSE INTENSITY, TOXICITY, AND OUTCOME IN OLIGODENDROGLIAL TUMORS (OG) TREATED WITH PCV REGIMEN Neuro-Oncology. 16: v49-v50. DOI: 10.1093/Neuonc/Nou243.18 |
0.351 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. AI-29 * ANGIOGENIC SWITCH FROM VEGFR2/HIF1 IN NEWLY DIAGNOSED GLIOBLASTOMA (GB) TO CXCR4-SDF1 PATHWAY IN RECURRENT PAIRED TUMOR AFTER RADIOTHERAPY (RT)-TEMOZOLOMIDE (TMZ) Neuro-Oncology. 16: v7-v7. DOI: 10.1093/Neuonc/Nou238.29 |
0.82 |
|
| 2014 |
Chinot O, Boudouresque F, Barrie M, Matta M, Boucard C, Loundou A, Figarella-Branger D, Ouafik L, Tabouret E. ASSOCIATION OF MATRIX METALLOPROTEINASE 2 (MMP2) BASELINE PLASMA LEVEL WITH RESPONSE AND SURVIVAL AND CHANGE OVERTIME IN PATIENTS TREATED WITH BEVACIZUMAB FOR RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 16: iii48-iii48. DOI: 10.1093/Neuonc/Nou209.23 |
0.53 |
|
| 2014 |
De Cock L, Sala Q, Barrie M, Boucard C, Metellus P, Tabouret E, Padovani L, Figarella-Branger D, Dufour H, Chinot O. P17.20 * PATTERNS OF CARE AND OUTCOME FOR PATIENTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: ii91-ii91. DOI: 10.1093/Neuonc/Nou174.350 |
0.632 |
|
| 2014 |
Autran D, Tabouret E, Barrie M, Boucard C, Terciolo A, Loundou A, Metellus P, Dufour H, Figarella-Branger D, Chinot OL. P08.07 * LEPTOMENINGEAL GLIOMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE STUDY OF 31 PATIENTS Neuro-Oncology. 16: ii51-ii52. DOI: 10.1093/Neuonc/Nou174.195 |
0.512 |
|
| 2014 |
Tabouret E, Boudouresque F, Denicolai E, Barrie M, Boucard C, Metellus P, Autran D, Figarella-Branger D, Ouafik L, Chinot O. P04.08 * PLASMA LEVELS AND TUMOR TISSUE RNA OF MMP2 AND MMP9 EXHIBIT SIMILAR DISTRIBUTION IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA (GB) Neuro-Oncology. 16: ii38-ii38. DOI: 10.1093/Neuonc/Nou174.140 |
0.411 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. P04.07 * EXPRESSION PROFILE OF ANGIOGENIC FACTORS IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: ii38-ii38. DOI: 10.1093/Neuonc/Nou174.139 |
0.747 |
|
| 2013 |
Tabouret E, Tassy L, Chinot O, Crétel E, Retornaz F, Rousseau F. High-grade glioma in elderly patients: can the oncogeriatrician help? Clinical Interventions in Aging. 8: 1617-24. PMID 24353408 DOI: 10.2147/Cia.S35941 |
0.396 |
|
| 2013 |
Vicier C, Tabouret E, Tallet A, Gonçalves A, Chetaille B, Viens P, Madroszyk A. BetaHCG secretion by a pulmonary adenocarcinoma. World Journal of Surgical Oncology. 11: 228. PMID 24034807 DOI: 10.1186/1477-7819-11-228 |
0.315 |
|
| 2013 |
Tabouret E, Metellus P, Tallet-Richard A, Figarella-Branger D, Charaffe-Jauffret E, Viens P, Gonçalves A. Surgical resection of brain metastases from breast cancer in the modern era: clinical outcome and prognostic factors. Anticancer Research. 33: 2159-67. PMID 23645770 |
0.381 |
|
| 2013 |
Tabouret E, Bauchet L, Carpentier AF. [Brain metastases epidemiology and biology]. Bulletin Du Cancer. 100: 57-62. PMID 23303801 DOI: 10.1684/Bdc.2012.1681 |
0.346 |
|
| 2013 |
Tabouret E, Boudouresque F, Callego Perez-Larraya J, Barrie M, Lombardi G, Matta M, Di Stefano AL, Labussiere M, Boucard C, Loundou A, Romain S, Carpentier AF, Sanson M, Ouafik L, Chinot OL. Association of matrix metalloproteinase 2 (MMP2) baseline plasma level to objective response (OR), progression free survival (PFS), and overall survival (OS) and changes under treatment in patients treated with bevacizumab (Bev) for recurrent high-grade glioma (HGG). Journal of Clinical Oncology. 31: 2024-2024. DOI: 10.1200/Jco.2013.31.15_Suppl.2024 |
0.361 |
|
| 2013 |
Metellus P, Tabouret E, Tallet A, Figarella D, Goncalves A, Barlesi F, Padovani L, Regis J, Fuentes S, Dufour H. Radiochirurgie du lit tumoral après résection chirurgicale d’une métastase cérébrale : un nouveau paradigme pour surseoir à la radiothérapie pancérébrale adjuvante Neurochirurgie. 59: 241. DOI: 10.1016/J.Neuchi.2013.10.052 |
0.597 |
|
| 2012 |
Tabouret E, Barrié M, Vicier C, Gonçalves A, Chinot O, Viens P, Madroszyk A. Association of carcinoid tumor and low grade glioma. World Journal of Surgical Oncology. 10: 236. PMID 23137305 DOI: 10.1186/1477-7819-10-236 |
0.386 |
|
| 2012 |
Colavolpe C, Chinot O, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Tabouret E, Mundler O, Figarella-Branger D, Guedj E. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan Neuro-Oncology. 14: 649-657. PMID 22379188 DOI: 10.1093/Neuonc/Nos012 |
0.514 |
|
| 2012 |
Tabouret E, Boudouresque F, Barrié M, Matta M, Boucard C, Loundou A, Ouafik M, Chinot O. Association of Matrix Metalloproteinase 2 (MMP2) Plasma Level with Response and Survival in Patients Treated with Bevacizumab for Recurrent High Grade Glioma Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)34314-3 |
0.42 |
|
| 2012 |
Tabouret E, Cauvin C, Fuentes S, Esterni B, Adetchessi T, Salem N, Madroszyk A, Gonçalves A, Viens P, Gravis-Mescam G. Limited Predictive Value of Scoring Systems for Metastatic Spinal Cord Compression (MSCC): Restrospective Monocentric Study Annals of Oncology. 23: ix150. DOI: 10.1016/S0923-7534(20)32994-X |
0.318 |
|
| Show low-probability matches. |